235 related articles for article (PubMed ID: 19475551)
1. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings.
Park YJ; Kim YA; Lee YJ; Kim SH; Park SY; Kim KW; Chung JK; Youn YK; Kim KH; Park DJ; Cho BY
Head Neck; 2010 Jan; 32(1):38-45. PubMed ID: 19475551
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
3. [Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].
Yang X; Liang ZY; Meng C; Liang J; Yu Z; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):398-403. PubMed ID: 23987486
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
5. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
7. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
8. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
10. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
Lupi C; Giannini R; Ugolini C; Proietti A; Berti P; Minuto M; Materazzi G; Elisei R; Santoro M; Miccoli P; Basolo F
J Clin Endocrinol Metab; 2007 Nov; 92(11):4085-90. PubMed ID: 17785355
[TBL] [Abstract][Full Text] [Related]
11. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
12. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
[TBL] [Abstract][Full Text] [Related]
13. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
14. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
[TBL] [Abstract][Full Text] [Related]
15. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
20. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
